

Contents

Acknowledgements	5
Abstract	7
Resumen	9
Resum	11
Contents	13
Figures List	17
Tables List	21
Acronyms	23
Structure of this thesis	25
Chapter 1. Introduction	27
1.1 Motivation	29
1.2 Objectives	30
Chapter 2. State of the Art	33
2.1 The heart	35
2.2 The cardiac tissue	37
2.2.1 Ion channels	39
2.2.2 The action potential	43
2.2.3 The electrocardiogram	47
2.3 Cardiac Disease	49
2.3.1 Cardiac structural disease	49
2.3.2 Long QT syndrome (LQTS)	49
2.4 Arrhythmia and Torsade-de-pointes	50
2.5 Antiarrhythmic therapy	52
2.5.1 Class I: sodium channel blockers	52
2.5.2 Class II: β -blockers	52
2.5.3 Class III: action potential prolongers	53
2.5.4 Class IV: calcium channel blockers	53
2.6 Modeling the cardiac electrophysiology	53
2.6.1 An introduction to cardiac modeling	53

2.6.2	Ion channel models.....	55
2.6.3	Cardiomyocyte action potential models	63
2.6.4	Tissue models	64
2.6.5	Channel-drug interaction models.....	66
Chapter 3.	Development of an in-silico TdP biomarker for early proarrhythmicity detection	71
3.1	Introduction.....	73
3.1.1	Objectives	75
3.2	Materials and methods	75
3.2.1	Models	75
3.2.2	Drug dataset.....	78
3.2.3	Simulation Protocols.....	80
3.2.4	Torsadogenic risk classification with Tx.....	81
3.3	Results.....	82
3.3.1	APD and QT	82
3.3.2	Proarrhythmicity assessment	91
3.4	Discussion.....	103
3.4.1	Findings	103
3.4.2	Limitations.....	105
3.4.3	Implementation.....	107
3.5	Conclusions.....	108
3.6	References of the drug dataset	109
Chapter 4.	Study and Modeling of a Channelopathy and Testing of Specific Treatments.....	115
4.1	Introduction.....	117
4.1.1	Long-QT syndrome and SCN5A V411M mutation.....	117
4.1.2	The late component of the sodium current (I_{NaL}).....	120
4.1.3	LQTS type 3 therapy	123
4.1.4	Objectives	125
4.2	Materials and Methods.....	126
4.2.1	Clinical characterization	126

4.2.2	Models	126
4.2.3	Optimization of the I_{Na} models	129
4.3	Results.....	132
4.3.1	QTc intervals of the patients.....	132
4.3.2	Overview of the optimization program.....	133
4.3.3	Wild type I_{Na} model.....	135
4.3.4	Mutation model	137
4.3.5	Flecainide model.....	139
4.3.6	Ranolazine model	143
4.3.7	Differences in flecainide and ranolazine mechanisms of action.....	143
4.4	Discussion.....	159
4.4.1	Main outcomes	159
4.4.2	Ranolazine, flecainide and LQT3	159
4.4.3	Personalized medicine	162
4.4.4	Implementation.....	164
4.4.5	Limitations.....	165
4.5	Conclusions.....	168
Chapter 5.	General Conclusions.....	169
Chapter 6.	Future work	174
Chapter 7.	Contributions	177
7.1	Journal Papers	179
7.1.1	Main contributions.....	179
7.1.2	Related contributions.....	179
7.2	Conference papers and communications.....	179
7.2.1	Main contributions.....	179
7.2.2	Related contributions.....	180
7.3	Research projects	180
7.4	Cardiac Safety prediction tool.....	181
Appendix.	Optimization procedure	183
A. 1.	General considerations.....	185

Prediction of the effects of drugs on cardiac activity using computer simulations.

A. 2. Patch clamp protocols	186
A. 3. Optimization of the wild-type (WT) I_{Na}	187
A. 4. Optimization of the SCN5A V411M mutation	192
A. 5. Optimization of Flecainide.....	193
A. 6. Optimization of Ranolazine	197
References	200